



United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.usplo.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/837,751	04/18/2001	Allan Green	45-00	8897
23713	7590 08/04/2004		EXAM	INER
GREENLEI	E WINNER AND SULLIV	MCELWAIN, ELIZABETH F		
5370 MANHATTAN CIRCLE SUITE 201			ART UNIT	PAPER NUMBER
BOULDER,	CO 80303	1638		
			DATE MAILED: 08/04/200	4

Please find below and/or attached an Office communication concerning this application or proceeding.

	Application No.	Applicant(s)				
	09/837,751	GREEN ET AL.				
Office Action Summary	Examiner	Art Unit				
	Elizabeth F. McElwain	1638				
The MAILING DATE of this communicati Period for Reply	on appears on the cover sheet with	the correspondence address				
A SHORTENED STATUTORY PERIOD FOR THE MAILING DATE OF THIS COMMUNICAT - Extensions of time may be available under the provisions of 37 after SIX (6) MONTHS from the mailing date of this communica - If the period for reply specified above is less than thirty (30) day - If NO period for reply is specified above, the maximum statutory - Failure to reply within the set or extended period for reply will, be Any reply received by the Office later than three months after the earned patent term adjustment. See 37 CFR 1.704(b).	TION. CFR 1.136(a). In no event, however, may a reption. s, a reply within the statutory minimum of thirty (y period will apply and will expire SIX (6) MONTHy statute, cause the application to become ABAI	ly be timely filed (30) days will be considered timely. HS from the mailing date of this communication. NDONED (35 U.S.C. § 133).				
Status						
1) Responsive to communication(s) filed or	1) Responsive to communication(s) filed on <u>10 May 2004</u> .					
,	Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under <i>Ex parte Quayle</i> , 1935 C.D. 11, 453 O.G. 213.					
closed in accordance with the practice u	nder Ex parte Quayle, 1935 C.D.	11, 453 O.G. 213.				
Disposition of Claims						
4) Claim(s) 109-146 is/are pending in the application. 4a) Of the above claim(s) 127-130 and 140-143 is/are withdrawn from consideration. 5) Claim(s) is/are allowed. 6) Claim(s) 109-126, 131-139 and 144-146 is/are rejected. 7) Claim(s) is/are objected to. 8) Claim(s) are subject to restriction and/or election requirement.						
Application Papers						
9) The specification is objected to by the Example 10) The drawing(s) filed on is/are: a)[Applicant may not request that any objection Replacement drawing sheet(s) including the 11) The oath or declaration is objected to by	accepted or b) objected to b to the drawing(s) be held in abeyand correction is required if the drawing(s	e. See 37 CFR 1.85(a). i) is objected to. See 37 CFR 1.121(d).				
Priority under 35 U.S.C. § 119						
12) Acknowledgment is made of a claim for the a) All b) Some * c) None of: 1. Certified copies of the priority documents of the priority documents. 2. Certified copies of the priority documents. 3. Copies of the certified copies of the application from the International. * See the attached detailed Office action for	uments have been received. uments have been received in Ap ne priority documents have been r Bureau (PCT Rule 17.2(a)).	oplication No received in this National Stage				
Attachment(s)						
1) Notice of References Cited (PTO-892) 2) Notice of Draftsperson's Patent Drawing Review (PTO-3) Information Disclosure Statement(s) (PTO-1449 or PTO Paper No(s)/Mail Date S. Patent and Trademark Office	Paper No(s)	Immary (PTO-413) /Mail Date formal Patent Application (PTO-152) 				

Art Unit: 1638

DETAILED ACTION

The amendment filed May 10, 2004 has been entered.

Claims 62-108 have been cancelled.

Claims 109-146 are newly submitted.

Election/Restrictions

Applicants' election with traverse of Group VI, SEQ ID NO: 3 and 4, in Paper No. 7 and 11 was acknowledged in the last office action, stating that the Examiner will examine SEQ ID NO: 3 and sequences coding for SEQ ID NO: 4, and claims relating to delta 12 fatty acid desaturase and claims relating to interrupted inverted repeats to the extent that they read on SEQ ID NO: 3 or 4.

Claims 127-130 and 140-143 are withdrawn as a non-elected invention wherein the claims are drawn to cotton seed oil, which would have been included in Group XIV in the restriction requirement.

This application contains claims 140-143 drawn to an invention nonelected with traverse in the reply filed on May 10, 2004. A complete reply to the final rejection must include cancelation of nonelected claims or other appropriate action (37 CFR 1.144) See MPEP § 821.01.

Claims 109-126, 131-139 and 144-146 are examined on the merits.

Claim Rejections - 35 USC § 112

1. The following is a quotation of the first paragraph of 35 U.S.C. 112:

Application/Control Number: 09/837,751

Art Unit: 1638

The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same and shall set forth the best mode contemplated by the inventor of carrying out his invention.

- 2. Claims 109-126 and 131-139 are rejected under 35 U.S.C. 112, first paragraph, as failing to comply with the written description requirement. The claim(s) contains subject matter which was not described in the specification in such a way as to reasonably convey to one skilled in the relevant art that the inventor(s), at the time the application was filed, had possession of the claimed invention. The claims are drawn to plants comprising specific levels of certain fatty acids, 58.5%, 66% or 68.9% oleic acid, for example. However, applicants have not indicated where in the specification or the originally filed claims there is support for these specific percentages of oleic acid.
- 3. Claims 109-126 and 131-139 and 144-146 are rejected under 35 U.S.C. 112, first paragraph, because the specification, while being enabling for a method of decreasing expression of a delta-12 fatty acid desaturase by transforming a cotton plant with a construct comprising either a full length delta-12 fatty acid desaturase gene in antisense or with a construct comprising inverted repeats of a delta-12 fatty acid desaturase gene that are 850 bp and optionally with a 92 bp intervening sequence, as well as the transgenic cotton plants and seeds produced by said method, does not reasonably provide enablement for the same method wherein the construct merely comprises a 20 nucleotide fragment of a delta-12 desaturase gene, as stated in the last office action for claims 62-65, 67-77, 79-85 and 101-108.

Application/Control Number: 09/837,751 Page 4

Art Unit: 1638

4. Applicant's arguments filed May 10, 2004 have been fully considered but they are not persuasive. Applicants assert that the newly filed claims do not teach use of constructs having as little as 20 nucleotides, and therefore the rejection does not apply. Applicants argue that the specification describes and exemplifies several gene constructs that reduce expression of the endogenous cotton ghFAD2-1 gene and that one skilled in the art would be able to make and use other constructs in a similar manner.

5. The Examiner maintains that the claims are now more broadly drawn to use of any gene construct that encodes a ribonucleotide molecule which reduces the expression of the endogenous cotton ghFAD2, and not limited to a ribonucleotide that is part of the ghFAD2 gene, while the specification only teaches a method of decreasing expression of a delta-12 fatty acid desaturase by transforming a cotton plant with a construct comprising either a full length delta-12 fatty acid desaturase gene in antisense or with a construct comprising inverted repeats of a delta-12 fatty acid desaturase gene that are 850 bp and optionally with a 92 bp intervening sequence, as well as the transgenic cotton plants and seeds produced by said method. The specification does not teach the use of other ghFAD2 constructs, much less the use of unrelated sequences that might produce a similar effect. Furthermore, applicants have argued at page 12 of the response with regard to the rejection under 35 USC 103 that reducing expression of the ghFAD2-1 is unpredictable given the high level of homology with the delta-12 desaturase family of mixed function mono-oxygenase enzymes in plants, which "are known to catalyze a range of reactions at the delta-12 position of C18 fatty acids including but not limited to desaturation, acetylenation, epoxygenation and hydroxylation", further stating that

Application/Control Number: 09/837,751

Art Unit: 1638

"demonstration that a gene from cotton is a member of the delta-12 desaturase . . . family does not predict that inhibition of the gene would increase oleic acid content of the cotton seed oil.

No claims are allowed.

6. Applicant's amendment necessitated the new ground(s) of rejection presented in this Office action. Accordingly, **THIS ACTION IS MADE FINAL**. See MPEP § 706.07(a). Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a).

A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any extension fee pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the date of this final action.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Elizabeth F. McElwain whose telephone number is (571) 272-0802. The examiner can normally be reached on increased flex time.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Amy Nelson can be reached on (571) 272-0804. The fax phone number for the organization where this application or proceeding is assigned is (703) 872-9306.

Application/Control Number: 09/837,751

Art Unit: 1638

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the receptionist whose telephone number is 703-308-0196.

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to (571) 272-0547.

Patent applicants with problems or questions regarding electronic images that can be viewed in the Patent Application Information Retrieval system (PAIR) can now contact the USPTO's Patent Electronic Business Center (Patent EBC) for assistance. Representatives are available to answer your questions daily from 6 am to midnight (EST). The toll free number is (866) 217-9197. When calling please have your application serial or patent number, the type of document you are having an image problem with, the number of pages and the specific nature of the problem. The Patent Electronic Business Center will notify applicants of the resolution of the problem within 5-7 business days. Applicants can also check PAIR to confirm that the problem has been corrected. The USPTO's Patent Electronic Business Center is a complete service center supporting all patent business on the Internet. The USPTO's PAIR system provides Internet-based access to patent application status and history information. It also enables applicants to view the scanned images of their own application file folder(s) as well as general patent information available to the public.

For all other customer support, please call the USPTO Call Center (UCC) at 800-786-9199.

Elizabeth F. McElwain, Ph.D.

Page 6

Primary Examiner Art Unit 1638

EFM